Beijing SL Pharmaceutical Co., Ltd. (SHE:002038)
China
· Delayed Price · Currency is CNY 6.27
+0.07 (1.13%)
At close: Mar 10, 2026
Beijing SL Pharmaceutical Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Net Income | 83.77 | -74.07 | 416.69 | 234.4 | 425.94 | 364.71 | Upgrade
|
| Depreciation & Amortization | 152.94 | 152.94 | 145.4 | 113.88 | 99.8 | 89.49 | Upgrade
|
| Other Amortization | 0.29 | 0.29 | 0.28 | 0.17 | 0.17 | 0.17 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | - | - | -0.21 | -3.22 | 0 | Upgrade
|
| Asset Writedown & Restructuring Costs | -0 | -0 | -0.01 | 0 | 0.02 | 0.02 | Upgrade
|
| Loss (Gain) From Sale of Investments | 159.17 | 159.17 | -239.47 | -98.13 | -209.01 | -239.36 | Upgrade
|
| Provision & Write-off of Bad Debts | 9.49 | 9.49 | 23.81 | 31.94 | 26.25 | 5.84 | Upgrade
|
| Other Operating Activities | -290.55 | 0.94 | 1.05 | -5.99 | -4.38 | -2.86 | Upgrade
|
| Change in Accounts Receivable | 62.45 | 62.45 | 19.66 | 82.88 | 108.64 | 198.78 | Upgrade
|
| Change in Inventory | -102.33 | -102.33 | -4.25 | 0.58 | -11.5 | -3.69 | Upgrade
|
| Change in Accounts Payable | 68.51 | 68.51 | 66.58 | 36.56 | 17.54 | -22.72 | Upgrade
|
| Change in Other Net Operating Assets | - | - | - | - | - | -0.12 | Upgrade
|
| Operating Cash Flow | 91.82 | 225.49 | 460.2 | 389.82 | 464.63 | 415.84 | Upgrade
|
| Operating Cash Flow Growth | -74.76% | -51.00% | 18.05% | -16.10% | 11.73% | -37.55% | Upgrade
|
| Capital Expenditures | -377.53 | -347.38 | -218.36 | -163.49 | -236.91 | -255.95 | Upgrade
|
| Sale of Property, Plant & Equipment | 0 | 0 | 0.01 | 1.47 | 7.49 | 0.01 | Upgrade
|
| Divestitures | - | - | - | -4.88 | - | - | Upgrade
|
| Investment in Securities | 81.58 | -33.46 | -86.95 | -384.76 | -0.96 | -560.67 | Upgrade
|
| Other Investing Activities | 164.14 | 169.29 | -39.35 | 11.25 | 32.55 | -25.53 | Upgrade
|
| Investing Cash Flow | -131.8 | -211.55 | -344.65 | -540.4 | -197.82 | -842.14 | Upgrade
|
| Short-Term Debt Issued | - | - | - | - | 5.5 | 7.17 | Upgrade
|
| Total Debt Issued | - | - | - | - | 5.5 | 7.17 | Upgrade
|
| Short-Term Debt Repaid | - | - | - | - | -14.5 | -8.27 | Upgrade
|
| Long-Term Debt Repaid | - | - | - | - | -0.4 | - | Upgrade
|
| Total Debt Repaid | - | - | - | - | -14.9 | -8.27 | Upgrade
|
| Net Debt Issued (Repaid) | - | - | - | - | -9.4 | -1.1 | Upgrade
|
| Common Dividends Paid | -20.55 | -154.1 | -102.74 | -102.74 | -102.93 | -205.82 | Upgrade
|
| Other Financing Activities | - | - | - | - | 9 | - | Upgrade
|
| Financing Cash Flow | -20.55 | -154.1 | -102.74 | -102.74 | -103.33 | -206.92 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0 | -0 | 0.03 | 0.1 | -0.02 | 0.08 | Upgrade
|
| Net Cash Flow | -60.52 | -140.17 | 12.84 | -253.21 | 163.45 | -633.15 | Upgrade
|
| Free Cash Flow | -285.7 | -121.89 | 241.84 | 226.33 | 227.72 | 159.89 | Upgrade
|
| Free Cash Flow Growth | - | - | 6.85% | -0.61% | 42.42% | -59.32% | Upgrade
|
| Free Cash Flow Margin | -49.38% | -18.46% | 23.75% | 21.55% | 18.75% | 14.37% | Upgrade
|
| Free Cash Flow Per Share | -0.27 | -0.12 | 0.24 | 0.22 | 0.22 | 0.16 | Upgrade
|
| Cash Income Tax Paid | 21.25 | 39.14 | 88.16 | 91.55 | 85.63 | 112.23 | Upgrade
|
| Levered Free Cash Flow | -581.12 | -260.4 | 186.77 | 121.34 | 113.97 | 94.8 | Upgrade
|
| Unlevered Free Cash Flow | -581.12 | -260.4 | 186.77 | 121.4 | 114.11 | 95.02 | Upgrade
|
| Change in Working Capital | -23.28 | -23.28 | 112.45 | 113.75 | 129.06 | 197.82 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.